CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms CORALLEEN
- 02 Jun 2052 Please do not auto-populate treatment arms from registry source.
- 08 Oct 2019 Planned End Date changed from 1 May 2019 to 20 Nov 2019.
- 08 Oct 2019 Status changed from recruiting to active, no longer recruiting.